RVAC Medicines Secures HSA Approval to Initiate Phase 1B Clinical Trial in Singapore

SINGAPORE, Feb. 20, 2023 /PRNewswire/ — RVAC Medicines Pte. Ltd. (RVAC), a messenger RNA (mRNA) technology platform company, announced today that it has secured the approval from the Health Sciences Authority (HSA) to initiate Phase 1B clinical trial in Singapore to evaluate the safety and immunogenicity of three COVID-19 mRNA vaccine candidates.